Aktis Oncology公布Aky-2519首次人体临床影像与剂量学数据，显示在表达B7-H3的肿瘤患者中实现强劲肿瘤摄取且正常组织暴露有限

美股速递05-22

Aktis Oncology公布了其靶向放射性药物候选产品Aky-2519的首次人体临床影像与剂量学数据。这些早期数据显示，在表达B7-H3的肿瘤患者中，Aky-2519表现出强劲且特异的肿瘤摄取，同时对正常组织的辐射暴露保持在有限水平。

B7-H3是一种在多种实体瘤中过度表达的肿瘤相关抗原，但在正常组织中表达有限，这使其成为肿瘤靶向治疗的理想靶点。Aky-2519旨在精准地将放射性同位素递送至表达B7-H3的肿瘤细胞。

公布的临床数据表明，Aky-2519能够有效地在肿瘤部位积聚，从而实现针对肿瘤的高剂量辐射，同时最大程度地减少对周围健康组织的潜在损伤。这种有利的剂量学特征对于开发高效且耐受性良好的癌症疗法至关重要。

该数据的公布标志着Aktis Oncology在推进其靶向放射性药物管线方面迈出了重要一步，为后续的临床开发提供了关键的早期概念验证。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1118503352?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-22 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118503352","market":"us","top_or_hot":-1,"title":"Aktis Oncology公布Aky-2519首次人体临床影像与剂量学数据，显示在表达B7-H3的肿瘤患者中实现强劲肿瘤摄取且正常组织暴露有限","media":"美股速递","content":"<p>Aktis Oncology公布了其靶向放射性药物候选产品Aky-2519的首次人体临床影像与剂量学数据。这些早期数据显示，在表达B7-H3的肿瘤患者中，Aky-2519表现出强劲且特异的肿瘤摄取，同时对正常组织的辐射暴露保持在有限水平。</p>\n<p>B7-H3是一种在多种实体瘤中过度表达的肿瘤相关抗原，但在正常组织中表达有限，这使其成为肿瘤靶向治疗的理想靶点。Aky-2519旨在精准地将放射性同位素递送至表达B7-H3的肿瘤细胞。</p>\n<p>公布的临床数据表明，Aky-2519能够有效地在肿瘤部位积聚，从而实现针对肿瘤的高剂量辐射，同时最大程度地减少对周围健康组织的潜在损伤。这种有利的剂量学特征对于开发高效且耐受性良好的癌症疗法至关重要。</p>\n<p>该数据的公布标志着Aktis Oncology在推进其靶向放射性药物管线方面迈出了重要一步，为后续的临床开发提供了关键的早期概念验证。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aktis Oncology公布Aky-2519首次人体临床影像与剂量学数据，显示在表达B7-H3的肿瘤患者中实现强劲肿瘤摄取且正常组织暴露有限</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAktis Oncology公布Aky-2519首次人体临床影像与剂量学数据，显示在表达B7-H3的肿瘤患者中实现强劲肿瘤摄取且正常组织暴露有限\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-22 05:22 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aktis Oncology公布了其靶向放射性药物候选产品Aky-2519的首次人体临床影像与剂量学数据。这些早期数据显示，在表达B7-H3的肿瘤患者中，Aky-2519表现出强劲且特异的肿瘤摄取，同时对正常组织的辐射暴露保持在有限水平。\nB7-H3是一种在多种实体瘤中过度表达的肿瘤相关抗原，但在正常组织中表达有限，这使其成为肿瘤靶向治疗的理想靶点。Aky-2519旨在精准地将放射性同位素递送至...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKTS","symbol_name":"Aktis Oncology","start_time":0,"source_url":"","article_id":"1118503352","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118503352","pubTimestamp":1779398536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Aktis Oncology公布了其靶向放射性药物候选产品Aky-2519的首次人体临床影像与剂量学数据。这些早期数据显示，在表达B7-H3的肿瘤患者中，Aky-2519表现出强劲且特异的肿瘤摄取，同时对正常组织的辐射暴露保持在有限水平。公布的临床数据表明，Aky-2519能够有效地在肿瘤部位积聚，从而实现针对肿瘤的高剂量辐射，同时最大程度地减少对周围健康组织的潜在损伤。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AKTS":"Aktis Oncology","BK4139":"生物科技","BK4148":"电子元件"},"translate_title":"Aktis Oncology Announces First Human Clinical Imaging and Dosimetry Data for Aky-2519, Showing Strong Tumor Uptake and Limited Normal Tissue Exposure in Patients with B7-H3-Expressing Tumors","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTS":1},"content_text":"Aktis Oncology公布了其靶向放射性药物候选产品Aky-2519的首次人体临床影像与剂量学数据。这些早期数据显示，在表达B7-H3的肿瘤患者中，Aky-2519表现出强劲且特异的肿瘤摄取，同时对正常组织的辐射暴露保持在有限水平。\nB7-H3是一种在多种实体瘤中过度表达的肿瘤相关抗原，但在正常组织中表达有限，这使其成为肿瘤靶向治疗的理想靶点。Aky-2519旨在精准地将放射性同位素递送至表达B7-H3的肿瘤细胞。\n公布的临床数据表明，Aky-2519能够有效地在肿瘤部位积聚，从而实现针对肿瘤的高剂量辐射，同时最大程度地减少对周围健康组织的潜在损伤。这种有利的剂量学特征对于开发高效且耐受性良好的癌症疗法至关重要。\n该数据的公布标志着Aktis Oncology在推进其靶向放射性药物管线方面迈出了重要一步，为后续的临床开发提供了关键的早期概念验证。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118503352","isCrawlerRequest":true}